After showing potent anti-tumour activity in vitro and in vivo in several B7-H3 expressing cancer types, B7-H3 targeting monoclonal antibodies (enoblituzumab) and chimeric antigen receptor (CAR)-T cell based therapies are now being tested in early phase trials [62]. This evidence concerns the gene CD276 and cancer.